Know Cancer

forgot password

Cytokines as Biomarkers and Therapeutic Targets in Paraneoplastic Opsoclonus-Myoclonus Syndrome (OMS)

1 Year
18 Years
Open (Enrolling)
Opsoclonus-myoclonus Syndrome

Thank you

Trial Information

Cytokines as Biomarkers and Therapeutic Targets in Paraneoplastic Opsoclonus-Myoclonus Syndrome (OMS)

In this translational research, immunological mechanisms that underlie the assault of the
immune system on the brain in paraneoplastic opsoclonus-myoclonus syndrome (OMS) are under
evaluation. To test our principal hypothesis that there is an imbalance of pro-inflammatory
(Th1) and anti-inflammatory (Th2) cytokines in OMS, a comprehensive cytokine panel will be
measured by enzyme-linked immunoadsorbent assay (ELISA) and multiplexed fluorescent
bead-based immunoassay detection (LUMINEX 100 Lab MAP system)in blood and CSF of 400
children. To test the second hypothesis that cytokines could serve as biomarkers of disease
activity in OMS, cytokine concentrations will be correlated with clinical variables, such as
disease severity, OMS duration, prior relapses, and remissions, as well as immunological
variables, such as lymphocyte subset analysis. The cytokine 'biomarker profile' could aid
decision making for early intervention by identifying children at high risk for relapse and
poor outcome and allow targeting of the most implicated inflammatory cytokines by cytokine
therapies. To test our third hypothesis that lack of response to immunotherapy is due in
part to failure to increase the expression of anti-inflammatory Th2 cytokines, we will
determine the longitudinal effects of standard immunotherapy, such as steroids, ACTH, IVIg,
and chemotherapy, given in the course of clinical care on the cytokine profile. This
research could lead to the application of commercially-available cytokines and cytokine
blockers or to the development of new ones for OMS.

Inclusion Criteria:

- Clinical diagnosis of OMS

Exclusion Criteria:

- Equivocal diagnosis

- Contraindications to lumbar puncture

- Treatment with agents outside the scope of the study

Type of Study:


Study Design:

Observational Model: Case Control, Time Perspective: Prospective

Outcome Measure:

Reduction in inflammatory cytokines

Outcome Time Frame:

6 and12 months

Safety Issue:


Principal Investigator

Michael R Pranzatelli, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

National Pediatric Myoclonus Center


United States: Institutional Review Board

Study ID:

Thrasher Award 02826-2



Start Date:

January 2008

Completion Date:

December 2013

Related Keywords:

  • Opsoclonus-myoclonus Syndrome
  • paraneoplastic
  • neuroblastoma
  • Kinsbourne syndrome
  • autoimmune disease
  • immunotherapy
  • ataxia
  • Myoclonus
  • Ocular Motility Disorders
  • Opsoclonus-Myoclonus Syndrome



National Pediatric Myoclonus Center, Dept. of Neurology, Southern Illinois University School of Medicine Springfield, Illinois  62702